Related Experiment Video
Updated: Aug 13, 2026

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
Published on: April 11, 2019
Clinical use of umbilical cord blood hematopoietic stem cells
Vanderson Rocha1, Eliane Gluckman,
1Eurocord Office Bone Marrow Transplant Hematology Department, Hôpital Saint Louis, Paris, France. vanderson.rocha@sls.ap-hop-paris.fr
Umbilical cord blood hematopoietic stem cells coming from related or unrelated donors are an alternative source of hematopoietic stem cells for patients undergoing transplantation for a wide variety of diseases. In the unrelated donor transplant setting, shorter time to transplant, which is particularly relevant to patients requiring urgent transplantation, and tolerance of 1-2 human leukocyte antigen mismatch, which increases the chance of finding a suitable donor, are evident advantages over bone marrow transplantation. The speed of engraftment is slower after cord blood transplantation but it is counterbalanced by a lower incidence of severe graft-versus-host disease. Cell dose and human leukocyte antigen are major factors influencing outcome after umbilical cord blood transplantation. Retrospective comparisons of clinical outcomes between unrelated cord blood and unrelated bone transplantation in children and adults have shown similar results, showing the value of this source of hematopoietic stem cell for transplantation. This review describes the recent clinical results and discusses developing research strategies aimed at optimizing the results of cord blood transplantation.
Umbilical cord blood hematopoietic stem cells coming from related or unrelated donors are an alternative source of hematopoietic stem cells for patients undergoing transplantation for a wide variety of diseases. In the unrelated donor transplant setting, shorter time to transplant, which is particularly relevant to patients requiring urgent transplantation, and tolerance of 1-2 human leukocyte antigen mismatch, which increases the chance of finding a suitable donor, are evident advantages over bone marrow transplantation. The speed of engraftment is slower after cord blood transplantation but it is counterbalanced by a lower incidence of severe graft-versus-host disease. Cell dose and human leukocyte antigen are major factors influencing outcome after umbilical cord blood transplantation. Retrospective comparisons of clinical outcomes between unrelated cord blood and unrelated bone transplantation in children and adults have shown similar results, showing the value of this source of hematopoietic stem cell for transplantation. This review describes the recent clinical results and discusses developing research strategies aimed at optimizing the results of cord blood transplantation.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Stem Cell Culture
Multipotency of Hematopoietic Stem Cells
iPS Cell Differentiation
Embryonic Stem Cells
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...

